非布司他对痛风有效果没？

Is febuxostat effective for gout? A phase III study showed that febuxostat 40 mg was as effective as allopurinol 300 mg in lowering urate in patients with gout.

In this study, a total of 2269 patients with gout (serum uric acid level ≥8.0 mg/dL at baseline) were randomized in a 1:1:1 ratio to receive febuxostat 40 mg, febuxostat 80 mg, or allopurinol 300 mg. Among these patients, 145 patients had moderate chronic kidney disease. The primary efficacy endpoint of the study was the percentage of all patients with a final serum uric acid level <6.0 mg/dL.

The study results showed that the percentages of patients in the febuxostat 40 mg, 80 mg, and allopurinol groups who achieved serum uric acid levels <6.0 mg/dL at 6 months were 45%, 67%, and 42%, respectively. The efficacy of reducing urate in the febuxostat 40 mg group was similar to that of the allopurinol group, but the efficacy of the febuxostat 80 mg group was better than that of the febuxostat 40 mg group and the allopurinol group (both comparisons were statistically significant). In an important subgroup of patients with unmet medical needs, that is, patients with chronic kidney disease, the urate-lowering efficacy of febuxostat 80 mg was greater (72%) than that of febuxostat 40 mg (50%) or allopurinol (42%); and in these patients, the urate-lowering efficacy of febuxostat 40 mg was also greater than that of allopurinol. In this study, the incidence of adverse events, including cardiovascular events, was similar across all groups.

Febuxostat is a drug that inhibits uric acid production and is suitable for the long-term treatment of hyperuricemia with gout symptoms. Febuxostat produced by Zydus Pharmaceuticals in India has a specification of 80mg*30 tablets/box. Its price is about 80$, and the specification of 40mg*100 tablets/box is about 200$. For detailed price information, you can consult the medical companion travel service.